Facioscapulohumeral muscular dystrophy: The unmet medical need

Kathryn R Wagner, MD, PhD
Director, Center for Genetic Muscle Disorders
Kennedy Krieger Institute
Professor, Neurology and Neuroscience
Johns Hopkins School of Medicine
Facioscapulohumeral Muscular Dystrophy (FSHD)

- Prevalence of ~1:8,000 - 1:20,000
- Autosomal dominant disorder of families
- Extremely disabling
- Can be life shortening for those with respiratory insufficiency
FSHD Phenotype

- Wide variability of severity
- Asymmetric involvement
- Majority present in adolescence/early adulthood
- Almost pure skeletal muscle disease: Usually no extramuscular symptoms
FSHD Phenotype

- Weakness of facial muscles: Transverse smile, eyelid closure weakness, buccal muscle weakness

Wagner, Continuum 2019
FSHD Phenotype

• Weakness of muscles of scapular fixation: scapular winging.
• Weakness and wasting and muscles overlying humerus: biceps/triceps

Wagner, Continuum 2019
FSHD Phenotype

- Pelvic girdle, foot dorsiflexor, abdominal muscle weakness may follow

Beevor sign

Wagner, Continuum 2019
Early or “Infantile Onset” FSHD

- Rapid progression with loss of ambulation
- Association with retinal vascular abnormalities and high tone hearing loss
- More likely to be associated with respiratory insufficiency
Current Management

- No good pharmacological agents to prevent muscle wasting and weakness
- Aquatic and physical therapy
  - Olsen et al., Aerobic training improves exercise performance in FSHD, Neurology 2005.
- Bracing
  - Foot drop: ankle foot orthoses
  - Abdominal laxity: abdominal binder
- For prevention of corneal abrasions
  - Lacrilube at night, artificial tears
Specific Treatments

- **Vascular telangiectasia**
  - Retinal exam with ophthalmologist
  - Fluorescein angiography if abnormal retinal exam or family history of Coat’s syndrome in FSHD
  - Laser treatments

- **Scapular Fixation**
  - Anticipated benefits: reduced pain,
    - Improved arm abduction/extension,
    - Less “winging”
  - Risks: surgical risks, infection, pain,
    - decreased pulmonary function, long rehab
  - No randomized trials
Scapulofixation on the right, winging on the left
FSHD1 is linked to a truncated repetitive region in the subtelomeric region of chromosome 4

Within each D4Z4 repeat unit is an open reading frame for a gene called **DUX4**
D4Z4 repeat truncation **AND** a permissive haplotype results in stable DUX4 transcript expression.

- **4qA**: DUX4 mRNA is stable
- **4qB**: DUX4 mRNA is degraded

~0.1% of muscle cells die
D4Z4 repeat truncation leads to changes in epigenetic regulation of the region

**Normal (11-100 repeats):**
Highly methylated, closed chromatin structure $\rightarrow$ transcriptional repression of DUX4

**FSHD1 (1-10 repeats):**
Loss of methylation, open chromatin structure $\rightarrow$ transcriptional activation of DUX4
FSHD1 vs FSHD2

Lek et al., Trends Mol Med 2016
Diagnosis of FSHD

• Clinical phenotype, normal to slightly elevated CK
• Genetic Testing FSHD1:
  – Determination of the number of D4Z4 units on chromosome 4 by Southern blot or genome-wide optical mapping
  – 1 to 10 repeats AND chromosome 4 permissive haplotype 4qA
  – 95% of FSHD patients carries one allele of 1-10 units
  – Early or “Infantile Onset” associated with 1-3 units
  – Mild or reduced penetrance associated with 8-10 units.
• Genetic Testing FSHD2:
  – Chromosome 4 permissive haplotype 4qA
  – Hypomethylation of D4Z4 repeat array
  – Heterozygous pathogenic variant in SMCHD1 or DNMT3B
Targets for FSHD Therapeutics

- 4q35 subtelomeric D4Z4 locus
  - Overexpression of SMCHD1
  - Modulation of histone acetylation
- DUX4
  - Knock down mRNA expression
  - Inhibit DUX4 protein/binding partners
- DUX4 target genes
- Downstream pathology
  - Inflammation
    - Immunomodulatory drugs
  - Atrophy
    - Anabolic agents
Conclusions

• FSHD is one of the most common muscular dystrophies
• It is marked by extensive muscle involvement with resulting disabilities
• The genetic cause is complex and the pathophysiology is incompletely understood
• There are insufficient meaningful treatments.